Introduction We conducted a systematic literature review to identify evidence for use of
vascular endothelial growth factor (VEGF)-targeted (anti-VEGF) treatment in patients with …

Cabozantinib is an inhibitor of multiple tyrosine kinases, including AXL, MET and VEGF
receptors. Here, we describe the rationale and design for the phase II CaboPoint trial …

Background Immuno-oncology combinations have achieved survival benefits in patients
with metastatic renal cell carcinoma (mRCC). Objective The ARON-1 study (NCT05287464) …

Aim In the registration trial, cabozantinib exposure≥ 750 ng/mL correlated to improved
tumor size reduction, response rate and progression free survival (PFS) in patients with …

Background Interindividual pharmacokinetic variability may influence the clinical benefit or
toxicity of cabozantinib in metastatic renal cell carcinoma (mRCC). We aimed to investigate …

Background There are limited data evaluating the activity of cabozantinib (CABO) as second
line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno …

Renal cancer is the seventh most common cancer in men and the tenth in women. The aim
of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma …

Background Adrenocortical carcinoma is a rare malignancy with poor response to systemic
chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma …

Patients with high-risk non-metastatic renal cell carcinoma (RCC) are at risk of metastatic
relapse following nephrectomy. Cabozantinib (CZ), a potent multitarget tyrosine kinase …

Results: The median PFS was 11 months (5; 23) and the median OS was 16 months (10; 42)
and differed significantly in the second and further lines of treatment. Progression in the …